{"transactions":[{"id":764738,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T23:45:05.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates."}],"balance_after":220000,"derivative":{"exercise_price":1.26,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001688712-26-000003","document":"form4-05262026_070502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000168871226000003/form4-05262026_070502.xml","form_type":"4"}},{"id":775062,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T20:29:14.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16991,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Certain of these shares are represented by previously reported restricted stock units (\"RSUs\"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the \"Company\"), Neocrine Biosciences, Inc. (\"Parent\") and Sigma Merger Sub, Inc. (\"Merger Sub\"), on May 18, 2026, Merger Sub merged with and into the Company (the \"Merger\"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001688712-26-000001","document":"form4-05182026_080509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000168871226000001/form4-05182026_080509.xml","form_type":"4"}},{"id":1014942,"issuer":{"id":7294,"kind":"organization","name":"FILANA THERAPEUTICS, INC."},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-22T22:15:16.000Z","date":"2025-10-21","kind":"grant","planned":false,"acquired":true,"shares":53000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests over three (3) years at a rate of 1/36th each month."}],"balance_after":53000,"derivative":{"exercise_price":3.98,"expiration_date":"2035-10-21","underlying":"Common Stock","underlying_shares":53000},"source":{"system":"sec-edgar","filing":"0001437749-25-031540","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925031540/rdgdoc.xml","form_type":"4"}},{"id":1117886,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T23:19:03.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":3991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 5, 2025 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. The Reporting Person previously elected to defer receipt of the shares of Common Stock underlying RSUs upon vesting. In accordance with the Reporting Person's deferral election the vested shares will be delivered to the Reporting Person when the Reporting Person ceases to provide services to the Issuer or upon a change of control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":16991,"source":{"system":"sec-edgar","filing":"0001415889-25-016355","document":"form4-06092025_110643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000141588925016355/form4-06092025_110643.xml","form_type":"4"}},{"id":1138191,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-22T21:06:38.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates."}],"balance_after":180000,"derivative":{"exercise_price":1.34,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000886744-25-000026","document":"wk-form4_1747947992.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674425000026/wk-form4_1747947992.xml","form_type":"4"}},{"id":1431368,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-16T22:18:09.000Z","date":"2024-08-15","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on August 15, 2025 and each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on August 15, 2025 and each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001415889-24-021503","document":"form4-08162024_100806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000141588924021503/form4-08162024_100806.xml","form_type":"4"}},{"id":1521320,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-10T20:05:22.000Z","date":"2024-05-09","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates."}],"balance_after":180000,"derivative":{"exercise_price":3.88,"expiration_date":"2034-05-08","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000950170-24-057796","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000095017024057796/ownership.xml","form_type":"4"}},{"id":1773335,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":207.2,"expiration_date":"2030-01-02","underlying":"Class B common stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1773334,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":55.73,"expiration_date":"2029-01-02","underlying":"Class B common stock","underlying_shares":17250},"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1773333,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":55.73,"expiration_date":"2029-01-02","underlying":"Class B common stock","underlying_shares":17250},"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1773332,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":55.73,"expiration_date":"2029-01-02","underlying":"Class B common stock","underlying_shares":34500},"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1773331,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":71300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":24.75,"expiration_date":"2027-12-06","underlying":"Class B common stock","underlying_shares":71300},"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1773330,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":36.71,"expiration_date":"2033-01-03","underlying":"Class A common stock","underlying_shares":63650},"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1773329,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1773328,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":121.29,"expiration_date":"2031-01-04","underlying":"Class A common stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1773327,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-09-26T20:30:27.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33805,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000089924323019542/doc4.xml","form_type":"4"}},{"id":1803627,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-08-17T20:35:43.000Z","date":"2023-08-16","kind":"sale","planned":false,"acquired":false,"shares":398,"price":168.3317,"value":66996.0166,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $168.28 to $168.49. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":33805,"source":{"system":"sec-edgar","filing":"0001209191-23-046282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123046282/doc4.xml","form_type":"4"}},{"id":1803626,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-08-17T20:35:43.000Z","date":"2023-08-15","kind":"sale","planned":false,"acquired":false,"shares":807,"price":169.0367,"value":136412.6169,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $169.00 to $169.06. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":34203,"source":{"system":"sec-edgar","filing":"0001209191-23-046282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123046282/doc4.xml","form_type":"4"}},{"id":1819229,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class B common stock","published_at":"2023-08-01T20:29:51.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-043986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123043986/doc4.xml","form_type":"4"}},{"id":1819228,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class B common stock","published_at":"2023-08-01T20:29:51.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":22.57,"value":902800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":40000,"derivative":{"underlying":"Class A common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-043986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123043986/doc4.xml","form_type":"4"}},{"id":1819227,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-01T20:29:51.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in twenty equal quarterly installments beginning on March 7, 2017."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":22.57,"expiration_date":"2026-12-07","underlying":"Class B common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-043986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123043986/doc4.xml","form_type":"4"}},{"id":1819226,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-08-01T20:29:51.000Z","date":"2023-07-28","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":164.5357,"value":6581428.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $165.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":35010,"source":{"system":"sec-edgar","filing":"0001209191-23-043986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123043986/doc4.xml","form_type":"4"}},{"id":1819225,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-08-01T20:29:51.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":75010,"source":{"system":"sec-edgar","filing":"0001209191-23-043986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123043986/doc4.xml","form_type":"4"}},{"id":1832243,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-07-10T20:42:40.000Z","date":"2023-07-06","kind":"grant","planned":false,"acquired":true,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units granted with performance criteria (PSUs). On December 17, 2020, the reporting person was granted 4,125 PSUs. On July 6, 2023, based on certain performance criteria, the PSUs vested as to 1,031 shares, with the remainder vesting 1/12th on each subsequent 3 month anniversary, subject to continued service through each vesting date."}],"balance_after":35010,"source":{"system":"sec-edgar","filing":"0001209191-23-041927","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123041927/doc4.xml","form_type":"4"}},{"id":1870946,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:53:42.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates."}],"balance_after":125000,"derivative":{"exercise_price":3.27,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001062993-23-012828","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000106299323012828/form4.xml","form_type":"4"}},{"id":1889088,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-05-17T20:21:18.000Z","date":"2023-05-16","kind":"sale","planned":false,"acquired":false,"shares":417,"price":80.955,"value":33758.235,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":30885,"source":{"system":"sec-edgar","filing":"0001209191-23-030167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123030167/doc4.xml","form_type":"4"}},{"id":1889087,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-05-17T20:21:18.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":894,"price":85.09,"value":76070.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":31302,"source":{"system":"sec-edgar","filing":"0001209191-23-030167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123030167/doc4.xml","form_type":"4"}},{"id":1952238,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-15T20:44:56.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":9317,"price":86.77,"value":808436.09,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $86.74 to $87.16. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":32196,"source":{"system":"sec-edgar","filing":"0001209191-23-018924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123018924/doc4.xml","form_type":"4"}},{"id":1963344,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class B common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-07","kind":"exercise","acquired":false,"shares":41630,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":41630},"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963343,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class B common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-07","kind":"exercise","acquired":true,"shares":41630,"price":21.05,"value":876311.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":41630,"derivative":{"underlying":"Class A common stock","underlying_shares":41630},"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963342,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-07","kind":"exercise","acquired":false,"shares":41630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested 37,500 shares on September 6, 2017 and in twelve equal quarterly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":21.05,"expiration_date":"2026-09-06","underlying":"Class B common stock","underlying_shares":41630},"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963341,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class B common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-06","kind":"exercise","acquired":false,"shares":48370,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":48370},"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963340,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class B common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-06","kind":"exercise","acquired":true,"shares":48370,"price":21.05,"value":1018188.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":48370,"derivative":{"underlying":"Class A common stock","underlying_shares":48370},"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963339,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-06","kind":"exercise","acquired":false,"shares":48370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested 37,500 shares on September 6, 2017 and in twelve equal quarterly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":41630,"derivative":{"exercise_price":21.05,"expiration_date":"2026-09-06","underlying":"Class B common stock","underlying_shares":48370},"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963338,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":200,"price":86.67,"value":17334.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $88.635 to $86.70. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":41513,"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963337,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":5793,"price":85.9,"value":497618.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.63 to $86.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":41713,"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963336,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":36049,"price":85.08,"value":3067048.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $84.58 to $85.56. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":47506,"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963335,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-07","kind":"exercise","acquired":true,"shares":41630,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":83555,"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963334,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":14820,"price":90.26,"value":1337653.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $89.91 to $90.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":41925,"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963333,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":40134,"price":89.3,"value":3583966.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $88.90 to $89.88. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":56745,"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1963332,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-08T22:17:37.000Z","date":"2023-03-06","kind":"exercise","acquired":true,"shares":48370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":96879,"source":{"system":"sec-edgar","filing":"0001209191-23-017258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123017258/doc4.xml","form_type":"4"}},{"id":1969169,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-03-06T21:28:34.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":2166,"price":88.2491,"value":191147.5506,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":48509,"source":{"system":"sec-edgar","filing":"0001209191-23-016278","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123016278/doc4.xml","form_type":"4"}},{"id":2067808,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right-to-buy)","published_at":"2023-01-04T21:11:55.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":63650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date."}],"balance_after":63650,"derivative":{"exercise_price":36.71,"expiration_date":"2033-01-03","underlying":"Class A common stock","underlying_shares":63650},"source":{"system":"sec-edgar","filing":"0001209191-23-000872","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123000872/doc4.xml","form_type":"4"}},{"id":2067807,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2023-01-04T21:11:55.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":15675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units, which vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date."}],"balance_after":50675,"source":{"system":"sec-edgar","filing":"0001209191-23-000872","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919123000872/doc4.xml","form_type":"4"}},{"id":2275412,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-11T22:14:04.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates."}],"balance_after":125000,"derivative":{"exercise_price":1.48,"expiration_date":"2032-05-09","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001062993-22-012151","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000106299322012151/form4.xml","form_type":"4"}},{"id":2444030,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-05T21:09:20.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date."}],"balance_after":70000,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-22-001638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919122001638/doc4.xml","form_type":"4"}},{"id":2444029,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2022-01-05T21:09:20.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units, which vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001209191-22-001638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919122001638/doc4.xml","form_type":"4"}},{"id":2715357,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-14T01:23:52.000Z","date":"2021-05-11","kind":"grant","acquired":true,"shares":83000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates."}],"balance_after":83000,"derivative":{"exercise_price":1.39,"expiration_date":"2031-05-10","underlying":"Common Stock","underlying_shares":83000},"source":{"system":"sec-edgar","filing":"0000886744-21-000039","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674421000039/edgar.xml","form_type":"4"}},{"id":2915837,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-06T21:10:03.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in sixteen equal quarterly installments beginning on April 4, 2021, subject to continued service through each vesting date."}],"balance_after":16500,"derivative":{"exercise_price":121.29,"expiration_date":"2031-01-04","underlying":"Class A common stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-21-001981","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919121001981/doc4.xml","form_type":"4"}},{"id":2986602,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class B common stock","published_at":"2020-11-10T22:30:34.000Z","date":"2020-11-09","kind":"exercise","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-20-057705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919120057705/doc4.xml","form_type":"4"}},{"id":2986601,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class B common stock","published_at":"2020-11-10T22:30:34.000Z","date":"2020-11-09","kind":"exercise","acquired":true,"shares":60000,"price":21.05,"value":1263000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":60000,"derivative":{"underlying":"Class A common stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-20-057705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919120057705/doc4.xml","form_type":"4"}},{"id":2986600,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-10T22:30:34.000Z","date":"2020-11-09","kind":"exercise","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One quarter of the options vested on September 6, 2017 and then in twelve equal quarterly installments thereafter, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":90000,"derivative":{"exercise_price":21.05,"expiration_date":"2026-09-06","underlying":"Class B common stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-20-057705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919120057705/doc4.xml","form_type":"4"}},{"id":2986599,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2020-11-10T22:30:34.000Z","date":"2020-11-09","kind":"sale","acquired":false,"shares":30000,"price":175,"value":5250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-057705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919120057705/doc4.xml","form_type":"4"}},{"id":2986598,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2020-11-10T22:30:34.000Z","date":"2020-11-09","kind":"sale","acquired":false,"shares":30000,"price":150.01,"value":4500300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-20-057705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919120057705/doc4.xml","form_type":"4"}},{"id":2986597,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A common stock","published_at":"2020-11-10T22:30:34.000Z","date":"2020-11-09","kind":"exercise","acquired":true,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001209191-20-057705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919120057705/doc4.xml","form_type":"4"}},{"id":3117576,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-09T22:11:09.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":83000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates."}],"balance_after":83000,"derivative":{"exercise_price":1.54,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":83000},"source":{"system":"sec-edgar","filing":"0000886744-20-000047","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674420000047/edgar.xml","form_type":"4"}},{"id":3318580,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-06T19:47:40.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in sixteen equal quarterly installments beginning on April 2, 2020, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":24000,"derivative":{"exercise_price":207.2,"expiration_date":"2030-01-02","underlying":"Class B common stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-20-001618","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919120001618/doc4.xml","form_type":"4"}},{"id":3374696,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-12T22:22:48.000Z","date":"2019-11-11","kind":"grant","acquired":true,"shares":17250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 2, 2019, the reporting person was granted an option to purchase 69,000 shares of Class B common stock. As previously reported, the option vests as to 34,500 shares in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. On October 14, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on January 14, 2020, subject to continued service through each vesting date. On November 11, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on February 11, 2020, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 2, 2019, the reporting person was granted an option to purchase 69,000 shares of Class B common stock. As previously reported, the option vests as to 34,500 shares in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. On October 14, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on January 14, 2020, subject to continued service through each vesting date. On November 11, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on February 11, 2020, subject to continued service through each vesting date."}],"balance_after":17250,"derivative":{"exercise_price":55.73,"expiration_date":"2029-01-02","underlying":"Class B common stock","underlying_shares":17250},"source":{"system":"sec-edgar","filing":"0001209191-19-056100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919119056100/doc4.xml","form_type":"4"}},{"id":3374695,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-12T22:22:48.000Z","date":"2019-10-14","kind":"grant","acquired":true,"shares":17250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 2, 2019, the reporting person was granted an option to purchase 69,000 shares of Class B common stock. As previously reported, the option vests as to 34,500 shares in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. On October 14, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on January 14, 2020, subject to continued service through each vesting date. On November 11, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on February 11, 2020, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 2, 2019, the reporting person was granted an option to purchase 69,000 shares of Class B common stock. As previously reported, the option vests as to 34,500 shares in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. On October 14, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on January 14, 2020, subject to continued service through each vesting date. On November 11, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on February 11, 2020, subject to continued service through each vesting date."}],"balance_after":17250,"derivative":{"exercise_price":55.73,"expiration_date":"2029-01-02","underlying":"Class B common stock","underlying_shares":17250},"source":{"system":"sec-edgar","filing":"0001209191-19-056100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919119056100/doc4.xml","form_type":"4"}},{"id":3497888,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Srock Option (right to buy)","published_at":"2019-06-07T23:18:14.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates."}],"balance_after":70000,"derivative":{"exercise_price":1.38,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000886744-19-000060","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674419000060/edgar.xml","form_type":"4"}},{"id":3575906,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-29T00:23:34.000Z","date":"2019-03-26","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in a series of three equal consecutive annual installments commencing from March 26, 2019, subject to the non-employee director providing continuous service to the Company through each vesting date."}],"balance_after":120000,"derivative":{"exercise_price":1.68,"expiration_date":"2029-03-25","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000886744-19-000041","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674419000041/edgar.xml","form_type":"4"}},{"id":3709164,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-03T19:15:13.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":34500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":34500,"derivative":{"exercise_price":55.73,"expiration_date":"2029-01-02","underlying":"Class B common stock","underlying_shares":34500},"source":{"system":"sec-edgar","filing":"0001209191-19-000757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919119000757/doc4.xml","form_type":"4"}},{"id":4139301,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-12-07T20:43:31.000Z","date":"2017-12-06","kind":"grant","acquired":true,"shares":71300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in sixteen equal quarterly installments beginning on March 6, 2018, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":71300,"derivative":{"exercise_price":24.75,"expiration_date":"2027-12-06","underlying":"Class B common stock","underlying_shares":71300},"source":{"system":"sec-edgar","filing":"0001209191-17-064372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919117064372/doc4.xml","form_type":"4"}},{"id":4528737,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":44451,"kind":"person","name":"Bir Dawn Carter","position":1,"cik":"0001688712","reported_name":"Bir Dawn Carter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-12-08T20:56:51.000Z","date":"2016-12-07","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in twenty equal quarterly installments beginning on March 7, 2017, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":40000,"derivative":{"exercise_price":22.57,"expiration_date":"2026-12-07","underlying":"Class B common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-16-154121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688712/000120919116154121/doc4.xml","form_type":"4"}}]}